Absolutely! Another quarter of solid earnings! Dr. D�Ambra should be proud to have created such a unique multi-faceted company � so much for those who said this is not a Biotechnology company! The news about BMS is just another example of the strength of this company. It could be that Wall Street is upset by the lack of specifics (has the number of phase III compounds increased � are they going to acquire a Nanotechnology company).